RxSight, Inc.
NASDAQ:RXST
54.16 (USD) • At close September 18, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 34.887 | 29.512 | 28.58 | 30.667 | 20.81 | 17.489 | 16.088 | 12.615 | 11.36 | 8.942 | 8.427 | 5.786 | 4.897 | 3.484 | 4.914 | 4.17 | 2.706 | 2.888 |
| Cost of Revenue
| 10.637 | 8.827 | 10.926 | 16.936 | 8.795 | 7.123 | 8.666 | 7.259 | 6.572 | 5.181 | 5.558 | 4.445 | 5.709 | 2.365 | 3.534 | 3.45 | 3.18 | 2.81 |
| Gross Profit
| 24.25 | 20.685 | 17.654 | 13.731 | 12.015 | 10.366 | 7.422 | 5.356 | 4.788 | 3.761 | 2.869 | 1.341 | -0.812 | 1.119 | 1.38 | 0.72 | -0.474 | 0.078 |
| Gross Profit Ratio
| 0.695 | 0.701 | 0.618 | 0.448 | 0.577 | 0.593 | 0.461 | 0.425 | 0.421 | 0.421 | 0.34 | 0.232 | -0.166 | 0.321 | 0.281 | 0.173 | -0.175 | 0.027 |
| Reseach & Development Expenses
| 8.291 | 8.031 | 7.341 | 7.101 | 7.401 | 7.208 | 6.681 | 6.388 | 6.192 | 6.719 | 5.916 | 5.377 | 6.563 | 6.643 | 5.272 | 5.801 | 5.084 | 5.777 |
| General & Administrative Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 24.292 | 23.324 | 21.165 | 19.142 | 18.239 | 16.255 | 15.731 | 14.926 | 14.388 | 13.62 | 11.619 | 9.076 | 6.502 | 5.611 | 4.403 | 3.825 | 3.249 | 3.698 |
| Other Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 32.583 | 31.355 | 28.506 | 26.243 | 25.64 | 23.463 | 22.412 | 21.314 | 20.58 | 20.339 | 17.535 | 14.453 | 13.065 | 12.254 | 9.675 | 9.626 | 8.333 | 9.475 |
| Operating Income
| -8.333 | -10.67 | -10.852 | -12.512 | -13.625 | -13.097 | -14.99 | -15.958 | -15.792 | -16.578 | -14.666 | -13.112 | -13.877 | -11.135 | -8.302 | -8.906 | -8.807 | -9.397 |
| Operating Income Ratio
| -0.239 | -0.362 | -0.38 | -0.408 | -0.655 | -0.749 | -0.932 | -1.265 | -1.39 | -1.854 | -1.74 | -2.266 | -2.834 | -3.196 | -1.689 | -2.136 | -3.255 | -3.254 |
| Total Other Income Expenses Net
| 2.27 | 1.579 | 1.657 | 0.109 | -0.362 | -0.115 | -0.615 | -0.86 | -0.94 | -1.014 | -1.069 | 1.503 | 1.214 | 5.018 | 35.071 | 39.518 | -4.178 | -7.407 |
| Income Before Tax
| -6.063 | -9.091 | -9.195 | -12.403 | -13.778 | -13.212 | -15.605 | -16.818 | -16.732 | -17.592 | -15.734 | -12.677 | -13.474 | -6.798 | 26.299 | 30.672 | -12.842 | -16.497 |
| Income Before Tax Ratio
| -0.174 | -0.308 | -0.322 | -0.404 | -0.662 | -0.755 | -0.97 | -1.333 | -1.473 | -1.967 | -1.867 | -2.191 | -2.751 | -1.951 | 5.352 | 7.355 | -4.746 | -5.712 |
| Income Tax Expense
| 0.016 | 0.009 | -0.018 | 0.012 | 0.026 | 1.622 | 0.005 | 0.86 | 0.196 | 0.004 | 0.002 | -0.004 | 0.003 | 0.007 | 0.004 | 0.008 | 0.04 | 0.005 |
| Net Income
| -6.079 | -9.1 | -9.177 | -12.415 | -13.804 | -14.834 | -15.61 | -17.678 | -16.732 | -17.596 | -15.734 | -12.673 | -13.477 | -6.805 | 26.295 | 30.664 | -12.882 | -16.502 |
| Net Income Ratio
| -0.174 | -0.308 | -0.321 | -0.405 | -0.663 | -0.848 | -0.97 | -1.401 | -1.473 | -1.968 | -1.867 | -2.19 | -2.752 | -1.953 | 5.351 | 7.353 | -4.761 | -5.714 |
| EPS
| -0.16 | -0.25 | -0.26 | -0.35 | -0.4 | -0.47 | -0.56 | -0.64 | -0.61 | -0.64 | -0.58 | -0.68 | -0.51 | -0.36 | 1.38 | 0.31 | -0.68 | -0.87 |
| EPS Diluted
| -0.16 | -0.25 | -0.26 | -0.35 | -0.4 | -0.47 | -0.56 | -0.64 | -0.61 | -0.64 | -0.58 | -0.68 | -0.51 | -0.36 | 1.38 | 0.31 | -0.68 | -0.87 |
| EBITDA
| -7.513 | -7.945 | -9.768 | -12.512 | -10.818 | -11.705 | -14.154 | -14.539 | -14.55 | -15.497 | -14.655 | -12.091 | -12.869 | -10.152 | -7.279 | -7.764 | -7.675 | -8.132 |
| EBITDA Ratio
| -0.215 | -0.269 | -0.342 | -0.408 | -0.52 | -0.669 | -0.88 | -1.153 | -1.281 | -1.733 | -1.739 | -2.09 | -2.628 | -2.914 | -1.481 | -1.862 | -2.836 | -2.816 |